BRIC-National Institute of Immunology
New Delhi-110067, INDIA

Notification for Inviting proprietary purchase Dated: 06.5.2026

NII is planning the procurement of the following item through proprietary mode.

Name of the item:

Custom Peptides (Qty-174)

Any other firm with items meeting the above-mentioned may contact to stores@nii.ac.in latest by 21.05.2026 or send the quotation (technical and price)

Aslam Ali
Consultant Stores
National Institute of Immunology
New Delhi-110067
011-26703-757
Stores@nii.ac.in

Technical Specifications for Custom Peptides

1. Custom synthesis of 174 peptides of a bacterial pathogen as synthetic peptides for use in human functional T-cell assays, including ELISPOT, intracellular cytokine staining (ICS), activation-induced marker (AIM), and proliferation assays.
2. The manufacturer must have a demonstrated track record of supplying peptide reagents used in high-impact peer-reviewed publications, including journals such as *Nature* and *Science*, supporting their reliability for advanced immunological research.
3. The manufacturer must hold a valid ISO 9001:2015 certification for peptide synthesis and related services, ensuring compliance with internationally accepted quality management systems.
4. Peptides shall be custom synthesized based on provided antigenic sequences (e.g., overlapping peptide libraries), with N-terminus as free amine and C-terminus as free acid unless otherwise specified.
5. Each peptide shall be supplied in a quantity of 1–4 mg (or as specified) in freeze-dried (lyophilized) form in individual vials to ensure stability and long-term storage.
6. Each peptide must have a minimum purity of ≥90%, validated using reverse-phase HPLC (C18 column, 220 nm detection), with accompanying HPLC chromatograms and mass spectrometry (MS) data for identity confirmation.
7. Manufacturer should have the ability to also synthesise peptide pools using sequential lyophilization of individual peptides, ensuring uniform peptide representation, high purity, and minimal batch-to-batch variability; for future orders. A simple solvent-based mixing shall not be acceptable.
8. Peptides shall be aliquoted in sterile, low-binding cryovials, with defined aliquot quantities to minimize freeze–thaw cycles and ensure reproducibility across assays.
9. The manufacturing process must follow low bioburden conditions to minimize contamination, and must ensure removal of synthesis-related impurities such as trifluoroacetate (TFA).
10. Each batch must be supplied with complete documentation, including Certificate of Analysis (CoA), HPLC reports, MS data, and product datasheets, ensuring traceability and quality verification.
11. The expected delivery timeline shall be approximately 6–8 weeks from the date of order confirmation, subject to synthesis complexity.
12. The manufacturer must ensure batch-to-batch consistency and reproducibility, with the capability to perform repeat synthesis and purification of difficult peptides without compromising quality.